These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 24938292)

  • 1. Feasibility of using the Multinational Association of Supportive Care in Cancer Antiemesis Tool for assessment of chemotherapy-induced nausea and vomiting at the Tom Baker Cancer Centre.
    Warr JK; Chambers CR; Cusano FL; Cuthbert CA; Mah MS
    J Oncol Pharm Pract; 2015 Oct; 21(5):348-57. PubMed ID: 24938292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool.
    Matsuda Y; Okita K; Furuhata T; Kutomi G; Yamashita K; Sato Y; Takimoto R; Hirata K
    Support Care Cancer; 2015 Nov; 23(11):3331-9. PubMed ID: 26003425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Quantification of Chemotherapy-Induced Nausea and Emesis between the Common Terminology Criteria for Adverse Events and the Multinational Association of Supportive Care in Cancer Antiemesis Tool.
    Uchida M; Nakamura T; Shima T; Yoshimoto G; Kato K; Hosohata K; Miyamoto T; Akashi K
    Biol Pharm Bull; 2018; 41(11):1667-1671. PubMed ID: 30381666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.
    Molassiotis A; Aapro M; Dicato M; Gascon P; Novoa SA; Isambert N; Burke TA; Gu A; Roila F
    J Pain Symptom Manage; 2014 May; 47(5):839-848.e4. PubMed ID: 24075401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Assessment of chemotherapy-induced nausea and vomiting(CINV)using MASCC antiemesis tool].
    Yamaguchi M; Ogawa T; Watanabe M; Anami S; Kamigaki S; Nishikawa N; Ono T; Furukawa H
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1691-6. PubMed ID: 19838029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The incidence of nausea in the absence of vomiting in patients receiving intravenous chemotherapy.
    Smit T; Kotze I; du Plessis J
    Ann Palliat Med; 2021 Mar; 10(3):2679-2686. PubMed ID: 33549001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gaps exist between patients' experience and clinicians' awareness of symptoms after chemotherapy: CINV and accompanying symptoms.
    Rha SY; Song SK; Lee CE; Park Y; Lee J
    Support Care Cancer; 2016 Nov; 24(11):4559-66. PubMed ID: 27278273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [An assessment tool for chemotherapy-induced nausea and vomiting and intervention outcomes].
    Aimono Y; Suzuki S; Nemoto M; Saito Y; Aoyama Y; Joko F; Maruyama T; Kamoshida T
    Gan To Kagaku Ryoho; 2013 Dec; 40(13):2551-4. PubMed ID: 24335368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative evaluation of 2 antiemesis tools for the prevention of chemotherapy-induced nausea and vomiting].
    Murata H; Teramoto Y; Kawashita M; Oi M; Kitaguchi T; Sasahira E; Masuda A; Satake Y; Enomoto S; Komai C; Udo M; Komuta K; Yamamoto K
    Gan To Kagaku Ryoho; 2014 Mar; 41(3):341-5. PubMed ID: 24743280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
    Shih V; Wan HS; Chan A
    Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychometric assessment of the Chinese version of the MASCC Antiemesis Tool (MAT) for measuring chemotherapy-induced nausea and vomiting.
    Tan JY; Suen LK; Molassiotis A
    Support Care Cancer; 2016 Sep; 24(9):3729-37. PubMed ID: 27039204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study.
    Gilmore JW; Peacock NW; Gu A; Szabo S; Rammage M; Sharpe J; Haislip ST; Perry T; Boozan TL; Meador K; Cao X; Burke TA
    J Oncol Pract; 2014 Jan; 10(1):68-74. PubMed ID: 24065402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.
    Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K
    Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries.
    Hsieh RK; Chan A; Kim HK; Yu S; Kim JG; Lee MA; Dalén J; Jung H; Liu YP; Burke TA; Keefe DM
    Support Care Cancer; 2015 Jan; 23(1):263-72. PubMed ID: 25120009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
    Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
    J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Perceptual gap between oncologists/oncology nurses and patients in the management and impact of chemotherapy/radiotherapy-induced nausea and vomiting: French results of the GAP survey].
    Morin S; Leurs I; Bousquet MN; Scotté F
    Bull Cancer; 2016 May; 103(5):469-77. PubMed ID: 27015797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychometric assessment of the Persian version of short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemetic tool.
    Eghbali M; Negarandeh R; Ebadi A; Bandari R; Mohammadzadeh F
    Support Care Cancer; 2020 Sep; 28(9):4353-4359. PubMed ID: 31907650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool.
    Molassiotis A; Coventry PA; Stricker CT; Clements C; Eaby B; Velders L; Rittenberg C; Gralla RJ
    J Pain Symptom Manage; 2007 Aug; 34(2):148-59. PubMed ID: 17509816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.
    Hilarius DL; Kloeg PH; van der Wall E; van den Heuvel JJ; Gundy CM; Aaronson NK
    Support Care Cancer; 2012 Jan; 20(1):107-17. PubMed ID: 21258948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey.
    Vidall C; Fernández-Ortega P; Cortinovis D; Jahn P; Amlani B; Scotté F
    Support Care Cancer; 2015 Nov; 23(11):3297-305. PubMed ID: 25953380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.